SBIR/STTR Research Award
Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials
Award amount
$2,999,168Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Biomedical Research Models, Inc.
- Proposal award date
- Not reported
- Contract end date
- 2019-05-31
- UEI
- EKMEBJEJWFN5
- Solicitation number
- PA10-123
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Globally, an estimated 16.2% of the human population is infected with HSV-2 including gt17% of the U.S. adult population. Genital herpes is associated with an increased risk of HIV acquisition and transmission and HSV-2infection can cause neonatal herpes with high infant mortality. HSV-2 infection in the adult population has increased substantially in the past two decades despite the availability of antiviral drugs. Although long-term antiviral drug treatment can lowerthe frequency of viral shedding and severity of recurrences, compliance and potential decreases in HSV-specific immune responses are problematic. The failure of antiviral drugs to prevent the spread of HSV-2 and the sheer magnitude of the public health problem associated with HSV-2 infection indicates a need for a safe and effective vaccine. The consensus of experts who attended the HSV workshop (Bethesda, October 2012) is that antibody response alone is not sufficient for protective immunity; mucosal a
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Selection of a device for intranasal administration of a mucosal vaccine for HSV
- Optimization of a mucosal RSV vaccine
- Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials
- A Mucosal RSV Vaccine
- Developing Small MIF Inhibitors for Rheumatoid Arthritis
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
20 SBIR/STTR records share this UEI (1997–2017). Reported award amounts total $15,083,676. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services